Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice
Despite considerable advances in pharmacotherapy and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose due to suboptimal medication adherence. Contributors to suboptimal adherence to insulin treatment include...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/4568903 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562301735010304 |
|---|---|
| author | Lutz Heinemann Christopher G. Parkin |
| author_facet | Lutz Heinemann Christopher G. Parkin |
| author_sort | Lutz Heinemann |
| collection | DOAJ |
| description | Despite considerable advances in pharmacotherapy and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose due to suboptimal medication adherence. Contributors to suboptimal adherence to insulin treatment include pain, inconvenience, and regimen complexity; however, a key driver is hypoglycemia. Improvements in the PK/PD characteristics of today’s SC insulins provide more physiologic coverage of basal and prandial insulin requirements than regular human insulin; however, they do not achieve the rapid on/rapid off characteristics of endogenously secreted insulin seen in healthy, nondiabetic individuals. Pulmonary administration of prandial insulin represents an attractive option that overcomes limitations of SC insulin by providing more a rapid onset of action and a faster return of action to baseline levels than SC administration of rapid-acting insulin analogs. This article reviews the unique PK/PD properties of a novel inhaled formulation that support its use in patient populations with T1D or T2D. |
| format | Article |
| id | doaj-art-fe8b687072824e59b55bddbbbf87fec8 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-fe8b687072824e59b55bddbbbf87fec82025-02-03T01:23:05ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/45689034568903Rethinking the Viability and Utility of Inhaled Insulin in Clinical PracticeLutz Heinemann0Christopher G. Parkin1Science & Co, Kehler Str. 24, 40468 Düsseldorf, GermanyCGParkin Communications Inc., 932 Vista Lago Way, Boulder City, USADespite considerable advances in pharmacotherapy and self-monitoring technologies in the last decades, a large percentage of adults with diabetes remain unsuccessful in achieving optimal glucose due to suboptimal medication adherence. Contributors to suboptimal adherence to insulin treatment include pain, inconvenience, and regimen complexity; however, a key driver is hypoglycemia. Improvements in the PK/PD characteristics of today’s SC insulins provide more physiologic coverage of basal and prandial insulin requirements than regular human insulin; however, they do not achieve the rapid on/rapid off characteristics of endogenously secreted insulin seen in healthy, nondiabetic individuals. Pulmonary administration of prandial insulin represents an attractive option that overcomes limitations of SC insulin by providing more a rapid onset of action and a faster return of action to baseline levels than SC administration of rapid-acting insulin analogs. This article reviews the unique PK/PD properties of a novel inhaled formulation that support its use in patient populations with T1D or T2D.http://dx.doi.org/10.1155/2018/4568903 |
| spellingShingle | Lutz Heinemann Christopher G. Parkin Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice Journal of Diabetes Research |
| title | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice |
| title_full | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice |
| title_fullStr | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice |
| title_full_unstemmed | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice |
| title_short | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice |
| title_sort | rethinking the viability and utility of inhaled insulin in clinical practice |
| url | http://dx.doi.org/10.1155/2018/4568903 |
| work_keys_str_mv | AT lutzheinemann rethinkingtheviabilityandutilityofinhaledinsulininclinicalpractice AT christophergparkin rethinkingtheviabilityandutilityofinhaledinsulininclinicalpractice |